# Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

> **NCT04108962** · PHASE4 · WITHDRAWN · sponsor: **Baylor Research Institute**

## Conditions studied

- ABPA
- Severe Asthma
- Allergic Bronchopulmonary Aspergillosis

## Interventions

- **DRUG:** Fasenra, 30 Mg/mL Subcutaneous Solution

## Key facts

- **NCT ID:** NCT04108962
- **Lead sponsor:** Baylor Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-23
- **Primary completion:** 2021-09-24
- **Final completion:** 2021-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficult to find eligible patients willing to participate.
- **Last updated:** 2022-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04108962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04108962, "Benralizumab in the Treatment of Patients With Severe Asthma With ABPA". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04108962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*